Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

SIMPLE SUMMARY: The ToGA trial has demonstrated, in HER2-expressing patients, that unresectable and advanced gastric cancer, chemotherapy and trastuzumab in combination increase overall survival, even if it is still unclear why after one year the same patients are non-responsive to trastuzumab treat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Laterza, Maria Maddalena, Ciaramella, Vincenza, Facchini, Bianca Arianna, Franzese, Elisena, Liguori, Carmela, De Falco, Stefano, Coppola, Paola, Pompella, Luca, Tirino, Giuseppe, Berretta, Massimiliano, Montella, Liliana, Facchini, Gaetano, Ciardiello, Fortunato, de Vita, Ferdinando
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8150287/
https://ncbi.nlm.nih.gov/pubmed/34066144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102339
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak